Quick Take: MindMed announced the approval of a study of mescaline and its role regarding the serotonin 5-HT2A receptor. This study has been approved by the local Swiss ethics committee, and will take place at a University Hospital in Basel, Switzerland. MindMed (Nasdaq: MNMD), a leading clinical stage psychedelic medicine company, announced today the approval by…